RHHBY Roche Holding Ltd ADR (Sponsored)

32.69
-0.03  -0%
Previous Close 32.72
Open 32.77
Price To Book 8.15
Market Cap 223298779559
Shares 6,830,797,784
Volume 1,265,201
Short Ratio
Av. Daily Volume 966,106

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due 1H 2019.
Mytesi (crofelemer)
Cancer related diarrhea (CRD)
Phase 3 data due 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2/3 data to be presented at AAN May 7, 2019 1pm.
RG7916 - SUNFISH
Spinal Muscular Atrophy (SMA)
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 3 data due in 2020.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
BLA filing announced February 5, 2019.
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
PDUFA date under priority review August 18, 2019.
Entrectinib
Solid tumors and ROS1-positive non-small cell lung cancer (NSCLC)
Phase 3 PFS endpoint met - PFS=6.3 vs. 5.6 months for chemo. HR 0.71.
Tecentriq+cb+pac/nab-pac - IMpower131
Squamous non-small cell lung cancer (NSCLC)
FDA Approval announced December 6, 2018.
Tecentriq + Avastin - IMpower150
Non-squamous non-small cell lung cancer (NSCLC)
PFS endpoint met. HR 0.74 - February 6, 2018.
TECENTRIQ (atezolizumab) - IMmotion151
Kidney cancer - renal cell carcinoma (mRCC)
Approval announced June 7, 2018.
MabThera/ Rituxan (rituximab)
Pemphigus vulgaris
Phase 3 data released July 19, 2018. PFS endpoint met, OS endpoint not yet met - final OS data due 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower132
Squamous non-small cell lung cancer (NSCLC)
FDA approval announced March 18, 2019.
Tecentriq+cb+etoposide - IMpower133
Squamous non-small cell lung cancer (NSCLC)
PDUFA date for sBLA September 2, 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
Phase 3 data due 2019.
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
FDA Approval announced October 4, 2018.
Hemlibra
Hemophilia
Phase 3 updated data due at 27 September-1 October 2019
Alecensa - ALEX
Anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-small cell lung cancer (NSCLC)
Phase 1b trial expansion announced June 1, 2018.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
FDA approval announced June 13, 2018.
Avastin (bevacizumab) + chemo
Ovarian cancer
Phase 3 enrollment has commenced - noted June 14, 2018.
Gantenerumab
Early Alzheimer's disease
FDA Approval announced October 24, 2018.
Baloxavir marboxil
Influenza
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
sNDA filing announced March 7, 2018.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
FDA Approval announced March 8, 2019.
TECENTRIQ (atezolizumab) plus Abraxane
Triple-negative breast cancer
Phase 3 data due 2019.
Tecentriq
Urothelial cancer
Phase 3 interim analysis passed.
Tecentriq + chemo - IMpassion 031
Neoadjuvant triple negative breast cancer
Phase 3 data due 2019.
Tecentriq + Avastin - IMbrave 150
Hepatocellular carcinoma
Phase 3 data to be presented at ASCO June 2019.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 2019.
Venclexta MIRROS
Acute myeloid leukemia (AML)
Phase 3 primary endpoint met.
Venclexta BELLINI
Multiple myeloma
PDUFA date under priority review August 19, 2019.
Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)
Diffuse large B-cell lymphoma (DLBCL)
PDUFA date for sNDA November 4, 2019.
Baloxavir marboxil
Influenza
Phase 3 OS update at ASCO 2019.
Tecentriq plus nab-paclitaxe - IMpassion 130
Triple-negative breast cancer
Phase 3 data due 2019.
Tecentriq - IMvigor211
Urothelial cancer
Phase 3 data due 2019.
Idasanutlin (RG7388) - MIRROS
Acute myeloid leukemia (AML)